Article Details

Pfizer, Sangamo set to resume gene therapy study after safety delay | BioPharma Dive

Retrieved on: 2022-09-23 21:50:06

Tags for this article:

Click the tags to see associated articles and topics

Pfizer, Sangamo set to resume gene therapy study after safety delay | BioPharma Dive. View article details on hiswai:

Excerpt

Concerns over blood clotting risk had derailed testing of the hemophilia treatment last year, leading the companies to adjust their trial protocol ...

Article found on: www.biopharmadive.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up